National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

poly-TLR agonist polyantigenic vaccine CADI-05
A poly-Toll-like receptor (TLR) agonist polyantigenic vaccine containing heat killed Mycobacterium indicus pranii (Mycobacterium w or Mw) with potential immunostimulating and antineoplastic activities. Upon administration, poly-TLR agonist polyantigenic vaccine activates a number of TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha; production of pro-inflammatory cytokines; upregulation of co-stimulatory molecules, enhanced T and B-cell stimulatory responses; T cell proliferation, and a Th1 immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in antineoplastic effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:CADI-05



Previous:Polo-like kinase 1 inhibitor GSK-461364, Polo-like kinase 1 inhibitor ON 01910.Na, poly AU, poly IC, poly ICLC
Next:polyamine analogue PG11047, polyethylene glycol 3350-based laxative, polyethyleneglycol-7-ethyl-10-hydroxycamptothecin, Polygam S/D, polyglutamate camptothecin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov